Symptom management: heart failure. Objectives. Epidemiology of advanced heart failure

Transcription

1 Symptom management: heart failure Margaret L. Campbell, PhD, RN, FAAN Detroit Receiving Hospital and Wayne State University, Detroit, MI September 18, 2009 Objectives Identify the most common physical symptoms associated with advanced heart disease Describe the etiology, assessment, and treatment of dyspnea, pain, and fatigue Discuss your cases Epidemiology of advanced heart failure 4.8 million Americans have heart failure ,00 new cases annually 450,000 NYHA Class IV Leading cause of hospitalization in people >65 years old 250,000 deaths per year Am Heart Assoc, 2003 update

2 Heart failure staging ACC/AHA Stage NYHA Functional Class Stage Description Class Description A Patients at high risk of developing HF because of the presence of conditions that are strongly associated with the development of HF. Such patients have no identifiable structural or functional abnormalities of the pericardium, myocardium, or cardiac valves, and have never shown signs or symptoms of HF. B Patients who have developed structural heart disease that is strongly associated with the development of HF but who have never shown signs or symptoms of HF. I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea. C D Patients who have current or prior symptoms of HF associated with underlying structural heart disease. Patients with advanced structural heart disease and marked symptoms of HF at rest despite maximal medical therapy and who require specialized interventions. II III IV Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased. Clinical trajectories for dying from heart disease Function Sudden Function Chronic decline Time Function Frail Time Time

3 Site of death by trajectory Function Chronic decline Determined by Rx goals ICU/acute care Home Extended care facility Time Site of death by trajectory Function Frail Home Extended Care facility Hospital Time Site of death by trajectory Function Sudden Time Home, Auto, Business, Public place Hospital ED Hospital ICU

4 It s a miracle you pulled through, just a few hours ago we were trying to decide whether to wring your neck! Importance of advance planning Patient needs to understand about heart failure Chronic Progressive Death can occur suddenly Distress can be controlled Along with prolongative, supportive Rx At end-stage Goals can be discussed in the hypothetical Just in case conversations Prevalence of pain across terminal illness (Solano et al. 2006) Diagnosis Prevalence # of studies N % Cancer ,379 AIDS Heart disease COPD Renal disease

5 Prevalence of dyspnea across terminal illnesses (Solano et al. 2006) Diagnosis Prevalence # of studies N % Cancer ,029 AIDS Heart disease COPD Renal disease Prevalence of fatigue across terminal illness (Solano et al. 2006) Diagnosis Prevalence # of studies N % Cancer AIDS Heart disease COPD Renal disease Dyspnea etiologies heart failure Left ventricular failure Pulmonary edema Diffusion defect Hypoxemia Inspiratory effort

6 Dyspnea Etiologies Right ventricular failure Liver congestion Ascites Reduced diaphragmatic excursion Inspiratory effort Respiratory myopathy Increased respiratory rate Inspiratory effort Dyspnea assessment Frequency With activity At rest Intensity Numeric rating Distress Numeric rating Common numeric dyspnea assessment tools Numeric rating system 0-10 Visual analog scale vertical or horizontal line anchored from 0-10 or mm

7 Vertical Dyspnea Visual Analog Scale Respiratory distress behaviors Tachypnea, tachycardia Accessory muscle use Elevation of clavicles Abdominal breathing Grunting at end-expiration Nasal flaring Fearful facial display Campbell,Res Nsg Health, 2007 Respiratory Distress Observation Scale Variable 0 points 1 point 2 points Total Heart rate per minute <90 beats beats 110 beats Respiratory rate per 18 breaths breaths >30 breaths minute Restlessness: nonpurposeful None Occasional, slight Frequent movements movements movements Accessory muscle use: None Slight rise Pronounced rise rise in clavicle during inspiration Paradoxical breathing None Present pattern Grunting at endexpiration: None Present guttural sound Nasal flaring: None Present involuntary movement of nares Look of fear None Eyes wide open, facial muscles tense, brow furrowed, mouth open

8 Dyspnea prevention Continue ACE inhibitors, inotropes, beta blockers, diuretics Maintain euvolemia Monitor daily weight Restrict sodium Balance rest with activity Dyspnea treatment Ascertain fluid status Restrict intake Diurese Vasodilate Oxygen Opioids Anxiolytics

9 Pain etiologies in heart failure Ischemia Coronary artery disease Iatrogenic Blood pressure cuff inflation Venipunctures Venous or arterial lines Pain assessment Numeric report Behaviors (Puntillo, Crit Care Med,2004) Grimacing Clenched fists Rubbing chest Closed eyes

10 Pain treatment Avoid iatrogenic causes Discontinue burdensome interventions Labs, X-rays, EKGs, continuous monitoring Invasive lines, catheters Balance rest with activity Nitrates Opioids Constipation and Impaction

11 Assessment Objective Hard, small, formed stools Abdominal palpation Rectal examination Abdominal radiograph Subjective Patient report about comfort and satisfaction Frequently unrecognized and untreated Nurses carry primary responsibility Assessing constipation Incomplete When did you last move your bowels? Have you moved your bowels today? Complete When was your last full, complete, and satisfying bowel movement? Prevention Standard bowel regimen at initiating of opioid regimen Stimulant laxative (sennoside) daily Stimulant laxative + stool softener (docusate) A comparison of sennosides with and without docusate in patients with cancer (Hawley, J Pall Med, 2008) Senna alone produced more bowel movements than in combination with docusate; no difference in cramping Exercise Fluids Fiber

12 Treatment Initial methods same as prevention Tegaserod (Zelmac, Zelnorm ) 5-HT4 serotonin agonist and prokinetic Parkinson s disease (Morgan et al. Clin Neuropharmacol, 2007) Inflammatory Bowel Disease (Foxx-Orenstein, et al. Neurogatroenterol Motil, 2007) Polyethylene glycol (MiraLax ) Drug induced constipation (DiPalma et al. South Med J, 2007) Methylnaltrexone (Relistor ) (Thomas, et al. New Eng J Med, 2008) OIC Terminally ill Fatigue etiology Myopathy Medication side effect Hypokalemia Sleep-disordered breathing Anemia of chronic disease

13 Fatigue treatment Exercise Chronic, stable heart failure? Last days..hours Consider discontinuing inotropes and pressors Will discontinuation exacerbate volume overload or chest pain? Are we waiting for someone from out of town? Continue diuretics Topical vasodilator if anuria De-activate ICD Continue supportive/palliative measures Oxygen Opioids Anxiolytics Senna References Dutka DP and Johnson MJ. Breathlessness in heart failure. In S. Booth and D. Dudgeon, eds. Dyspnoea in advanced disease. Oxford University Press, Goodlin S. Palliative care in congestive heart failure. Journal of the American College of Cardiology, 2009;54: Solano JP, et al. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease, and renal disease. Journal of Pain and Symptom Management, 2006;31:58-69.

14